Horrible Label! 150 and not 135 and only Secondary!

Quote


















So, there's actually no mention of primary or secondary and that's by design. The indication is for lowering risk of MI, Stroke, Revasc and Angina (not death though) in patients with established ASCVD (subjective criteria here) and TG's > 150. OR for patients with Diabetes and 2 additional risk factors... Smoking, BMI > 25, Family history, Calcium scores maybe.... who knows. We have a BROAD way of looking at this. Patients must be on maximally tolerated statin therapy (0 can be a maximum tolerance). We have literally more patients available to us than freaking statins. GO HOME TROLLS.

THAT BEING SAID

In my part of the world they need to support our access to large hospital system based physicians that are locked out from us. They also need to work on managed care in all the red states. There's a blockbuster opportunity here but they need to take action on MC issues now. We have the actorsin place but they're useless without quality stagehands. Working for small pharma with a good product can be seriously challenging.
 






anonymous said:
So, there's actually no mention of primary or secondary and that's by design. The indication is for lowering risk of MI, Stroke, Revasc and Angina (not death though) in patients with established ASCVD (subjective criteria here) and TG's > 150. OR for patients with Diabetes and 2 additional risk factors... Smoking, BMI > 25, Family history, Calcium scores maybe.... who knows. We have a BROAD way of looking at this. Patients must be on maximally tolerated statin therapy (0 can be a maximum tolerance). We have literally more patients available to us than freaking statins. GO HOME TROLLS.

THAT BEING SAID

In my part of the world they need to support our access to large hospital system based physicians that are locked out from us. They also need to work on managed care in all the red states. There's a blockbuster opportunity here but they need to take action on MC issues now. We have the actorsin place but they're useless without quality stagehands. Working for small pharma with a good product can be seriously challenging.
Click to expand...

Pfizer or Merck and their worldwide juggernaut will take this to the next level.They know how to get in and support large hospital systems. It’s time for the Big Boys to takeover this 5-10B per drug.
 












BASF friends say they can’t even get a foot in the door to jumpstart API talks again. Amarin apologetic while slamming door. WTF? They were set to be our biggest partner and we won’t give them the time of day despite needing expansion? BP?
 












Top Bottom
Back
Quote